文献速递糖尿病肥胖与代谢综合征

替尔泊肽与司美格鲁肽对肠道微生物组分类及预测功能的纵向影响:OMDOT-1随机对照试验的探索性二次分析

Longitudinal Taxonomic and Predicted Functional Gut Microbiome Responses to Tirzepatide and Semaglutide: An Exploratory Secondary Analysis of the OMDOT‐1 Randomized Controlled Trial
RSS 订阅 · Diabetes, Obesity and Metabolism · 2026-11-09

该探索性二次分析纳入36名2型糖尿病参与者,比较替尔泊肽、司美格鲁肽与常规治疗在16周内五个时间点的粪便微生物组。β多样性无显著组间差异;α多样性主要在替尔泊肽组升高,且与对照组存在显著时间×治疗交互作用。两药在多个属的纵向轨迹与对照组不同,预测功能变化模式 broadly 相似。

要点

  • β多样性无显著组间差异,α多样性主要在替尔泊肽组升高。
  • 替尔泊肽与司美格鲁肽在多个属的纵向轨迹与对照组不同。
  • 两药预测功能变化方向一致率67.1%,涉及能量与碳水化合物代谢。

核心结论

  • 替尔泊肽与司美格鲁肽伴随部分不同的分类学变化,同时预测功能模式大致相似。
  • 这些纵向发现与第16周鸟枪法宏基因组终点分析互补但保持区别。

研究设计与样本

  • 探索性二次分析,纳入OMDOT-1随机对照试验中36名参与者,比较替尔泊肽、司美格鲁肽与常规治疗。
  • 16周内五个时间点采集粪便样本,行16S rRNA基因测序。
  • 属水平特征用MaAsLin2筛选,候选属进一步用纵向混合效应模型评估;预测微生物功能用PICRUSt2推断并用MaAsLin2分析。
  • 主要分析校正基线体重指数,探索性敏感性分析额外校正体重变化和糖化血红蛋白变化。

主要发现

  • β多样性未观察到显著组间差异。
  • α多样性主要在替尔泊肽组升高,与对照组存在显著时间×治疗交互作用。
  • 多个属的纵向轨迹相对对照组存在差异,包括Romboutsia_B、Barnesiella和Ruminococcus_E在两种治疗下以及Vescimonas在替尔泊肽下(q < 0.05)。
  • 在2106个预测EC特征中,替尔泊肽与司美格鲁肽的纵向效应呈正相关(方向一致67.1%;Pearson r = 0.450,p < 0.001)。
  • 治疗vs对照分析识别出涉及能量和碳水化合物代谢的预测功能变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ABSTRACT Aims Glucagon-like peptide-1-based therapies improve metabolic outcomes, but longitudinal gut microbiome dynamics remain poorly characterized. We compared taxonomic and predicted functional microbiome responses to tirzepatide and semaglutide in Type 2 diabetes. Materials and Methods This exploratory secondary analysis included 36 participants from a randomized controlled trial comparing tirzepatide, semaglutide and conventional treatment. Faecal samples were collected at five time points over 16 weeks and analyzed by 16S rRNA gene sequencing. Genus-level features were screened using MaAsLin2, and candidate genera were further evaluated using longitudinal mixed-effects models. Predicted microbial functions were inferred using PICRUSt2 and analyzed using MaAsLin2. Primary analyses were adjusted for baseline body mass index, with exploratory sensitivity analyses additionally adjusted for changes in body weight and haemoglobin A1c. Results No significant between-group differences in beta diversity were observed. Alpha diversity increased predominantly in the tirzepatide group, with a significant time-by-treatment interaction versus control. Longitudinal trajectories relative to the control group differed for several genera, including Romboutsia_B, Barnesiella and Ruminococcus_E with both treatments and Vescimonas with tirzepatide (q < 0.05). Across 2106 predicted EC features, longitudinal effects were positively correlated between tirzepatide and semaglutide (67.1% concordant direction; Pearson r = 0.450, p < 0.001). Treatment-versus-control analyses identified predicted functional changes involving energy and carbohydrate metabolism. Conclusions Tirzepatide and semaglutide were associated with partially distinct taxonomic changes, accompanied by broadly similar predicted functional patterns. These longitudinal findings complement, while remaining distinct from, Week-16 shotgun metagenomic endpoint analyses. Trial Registration Japan Registry of Clinical Trials (jRCT), jRCT1051240017

来源:Diabetes, Obesity and Metabolism,查看原文。版权归原作者所有。

引用

  1. Diabetes, Obesity and Metabolism:Longitudinal Taxonomic and Predicted Functional Gut Microbiome Responses to Tirzepatide and Semaglutide: An Exploratory Secondary Analysis of the OMDOT‐1 Randomized Controlled Trial

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。